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Abstract 
We present here a case of diffuse tracheobronchial wall spread of metastatic breast 
cancer who was successfully treated with trastuzumab plus vinorelbine chemotherapy. 
The patient had a left radical mastectomy for breast cancer in March 2000 and developed 
persistent cough and dyspnea in November 2006. Pulmonary function test demonstrated 
an obstructive pattern. Chest computed tomography showed a wall thickening of 
trachea and right side bronchus, but radiographic findings including 
18F-fluorodeoxyglucose positron emission tomography failed to detect the locations of 
disease in the lung. The findings on bronchofiberscopy showed edematous 
tracheobronchial mucosa, but also failed to visually detect direct masses. Transbronchial 
biopsy specimens revealed involvement of metastatic breast cancer. The patient was 
treated with trastuzumab plus vinorelbine chemotherapy and the wall thickening of 
bronchial tree and clinical symptoms were improved. Although endobronchial 
metastasis in metastatic breast cancer is not uncommon, diffuse spread without forming 
intraluminal mass is extremely rare. The pattern of endobronchial metastasis should be 
considered in patients with malignancies even when radiographic abnormalities are 
undetectable. 
 
Introduction 
The lungs are often involved in extrapulmonary malignancies, but 
endotracheal/endobronchial metastases are uncommon [1–3]. The diagnosis is made by 
presence of bronchoscopically visible tumors on the bronchus and histological findings 
identical to primary tumors at another site [1–3]. The invasion of the endobronchial wall  
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has been thought to be from parenchymal or mediastinal lymph node metastasis, and/or 
from both. In general, radiographic examinations of chest radiograph or computed 
tomography (CT) revealed the abnormal findings, such as atelectasis, hilar or mediastinal 
lymphadenopathy, intraluminal tumor or pulmonary nodules [1–4]. We encountered a 
case of diffuse tracheobronchial wall metastasis of breast cancer, in which radiograph and 
endoscopy failed to detect direct masses. The patient presented persistent cough, dyspnea 
and an obstructive pattern in pulmonary function test, which were indistinguishable from 
other pulmonary diseases. The rare manifestation as in this case is a pitfall in diagnosis 
and management in patients with breast cancer. 
Case Presentation 
A 54-year-old woman was admitted to our hospital in November 2006 because of cough and 
dyspnea on exertion. She had had a left radical mastectomy for breast cancer in March 2000. 
Postoperative radiation (54 Gy) was administered because of histological evidences of metastasis in 
axillary lymph nodes. The patient was initially referred to our hospital in October 2002 because of an 
abnormal finding on chest radiograph during follow-up. She was asymptomatic and a 20-mm nodule 
was observed in the right S2 without any hilar or mediastinal lymphadenopathy. Bronchoscopic 
examination did not show any abnormalities on the proximal bronchus, but revealed malignant cells 
(adenocarcinoma) from the nodule. Right upper lobectomy was performed and the histological findings 
confirmed metastatic breast cancer. The resection margin was free from tumor involvement and there 
were no abnormal findings on other radiographic examinations, including bone scan, brain and 
abdominal CT. The immunohistochemical examination revealed human epidermal growth factor 
receptor-2 (HER-2) overexpression and was negative for estrogen receptor and progesterone receptor. 
Postoperative adjuvant chemotherapy was performed with 6 cycles of epirubicin plus 
cyclophosphamide chemotherapy and followed by trastuzumab plus paclitaxel therapy until October 
2004. There were no clinical signs of relapsing breast cancer including radiographic findings and 
increases in specific tumor makers. 
However, the patient presented persistent cough and developed exertional dyspnea in November 
2006. Pulmonary function test showed an obstructive pattern (forced expiratory volume in 1 s (FEV1), 
1.38 l and 59.2% of predicted). Physical and laboratory examination identified no abnormal findings 
(chest CT scan at the time is shown in fig. 1). The thickened wall in trachea and right bronchus were 
observed, but no abnormal masses were detected in both lungs and mediastinum. 
18F-
fluorodeoxyglucose positron emission tomography (FDG-PET) showed a weak accumulation of right 
hilar lesions, but no abnormal findings in the lung and other organs (fig. 2). These findings were 
inadequate for diagnostic criteria in the presence of abnormality on chest CT and FDG-PET. Since her 
symptoms persisted, a flexible bronchoscopy was performed. The bronchoscopic findings revealed 
edematous mucosa throughout the tracheobronchial tree without any elevated lesions suggesting a 
malignancy (fig. 3). Since brushing cytology revealed a presence of malignant cells (adenocarcinoma), 
subsequently transbronchial core needle biopsy from the spar between middle and basal bronchus was 
performed. The histological diagnosis of metastatic lung tumor was obtained and immunohistochemical 
examination revealed the same pattern as that in previously excised lung tumor (HER-2 (+++), ER (–) 
and PR (–); fig. 4). In addition, immunoreactivity for thyroid transcription factor-1 (TTF-1), a useful 
marker for distinguishing primary and metastatic lung tumor [5], was negative (fig. 4c). Thus, diagnosis 
of metastatic breast cancer was confirmed by the histological and immunohistochemical examination. 
The patient was treated with trastuzumab (2 mg/kg every week) plus vinorelbine (20 mg/m
2 day 1, 8, 15, 
every 4 weeks). No adverse effects, including cardiotoxicity, neurotoxicity or hematotoxicities, have 
been observed. After 8 courses of chemotherapy, the tracheobronchial wall thickening on chest CT was 
normalized (fig. 5) and there was an improvement of obstructive air limitation (FEV1, 1.90 l and 81.5% 
of predicted). The patient has been treated with this regimen and is still alive 16 months after the 
initiation of chemotherapy. 
Discussion 
Among the primary tumors, breast cancer is the most common tumor causing 
endobronchial metastasis [1–4]. In the present case, tracheobronchial wall thickening and  
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edematous mucosa were observed on chest CT and bronchoscopy, respectively. However, 
these findings were not specific for suspecting a malignant disease, because there were no 
lesions suggesting a presence of malignancy. Indeed, it was difficult for us to make a 
clinical diagnosis before the histological results of biopsy specimens. Thus, we emphasize 
that diffuse bronchial wall thickening on chest CT is included as a radiographic 
manifestation in endobronchial metastasis. Among all the imaging modalities, whole-
body PET has a new and unique role in the identification of active status of malignant 
diseases [6, 7]. However, FDG-PET also failed to detect the bronchial involvement in the 
present case. Taken together, the present case highlights the importance of bronchoscopy 
in the diagnosis of endobronchial metastasis in patients with a history of malignancies. 
In the present case, radiographic aspects and the improvement of wall thickening after 
chemotherapy were observed in the lower trachea and right main bronchus, suggesting 
main involvement on the right side. As a possible developmental mode of the metastasis 
in the present case, residual or newly developed malignant cells even after upper 
lobectomy and subsequent chemotherapy might extend along the bronchus or submucosa 
invasion. Several studies of endobronchial metastasis indicated that the involved lesions 
were observed predominantly in right sides [1–3], which was consistent with our case. 
The reason for this is still unclear and the metastatic route in our case is still speculated 
on. The involved and developmental pattern in the present case seemed to be a subtype of 
bronchial invasion by parenchymal lesion proposed by Kiryu et al. [1] and Akoglu et al. 
[3]. However, our case indicates that serial submucosal invasion along the bronchial wall 
without intraluminal polypoid growth should be discriminated in metastatic breast 
cancer. 
Bronchoscopic and histological findings may be insufficient to distinguish primary 
from metastatic tumor on bronchus in some clinical situations [1–3]. In the present case, 
a history of the underlying diseases and detailed immunohistochemical examination such 
as HER-2 or TTF-1 was useful to a further appropriate diagnosis and chemotherapeutic 
strategy. HER-2-positive breast cancer tends to be more aggressive than other types of 
breast cancer [8, 9]. The combination of trastuzumab and chemotherapy is significantly 
superior to chemotherapy alone in terms of both response rates and survival [8, 9]. The 
patient was treated with trastuzumab plus vinorelbine, and this resulted in the 
improvement of tracheobronchial wall thickening and obstructive pulmonary function, 
suggesting that HER-2 is a useful biological marker for selecting a proper therapy. 
In summary, the case presented here suggests that diffuse endobronchial metastasis 
without grossly visible findings on bronchoscopy could occur in patients with 
malignancies, especially breast cancer. When radiographic examinations do not reveal 
intraluminal tumors, lymphadenopathy, or pulmonary metastasis, the possibility of 
diffuse endobronchial wall spread should be included in the diagnosis and management 
of patients with breast cancer. 
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Fig. 1. Chest computed tomography demonstrated a tracheobronchial wall thickness before 
chemotherapy. Arrows indicate the involved lesions. 
 
 
 
Fig. 2. 
18F-Fluorodeoxyglucose positron emission tomography scanning before chemotherapy showing 
no abnormal findings. 
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Fig. 3. Bronchoscopic findings of carina indicating only edematous mucosa (a) and right spur between 
middle and basal bronchus showing submucosal edema and mucosal reddish in right bronchi (b). 
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Fig. 4. Histological findings of bronchial wall specimens showed infiltration of the adenocarcinoma (a). 
The immunohistological finding was positive for human epidermal growth factor receptor-2 (b) and 
negative for thyroid tissue factor-1 (c). ×200. 
 
 
 
Fig. 5. Chest computed tomography demonstrated improved tracheobronchial wall thickening after 
chemotherapy. 
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